Biosimilars: Are They Really Safe?
Cancer Treat Res
; 171: 61-73, 2019.
Article
en En
| MEDLINE
| ID: mdl-30552657
ABSTRACT
An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Biosimilares Farmacéuticos
/
Neoplasias
Límite:
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article